SG165157A1 - Identification of genes - Google Patents
Identification of genesInfo
- Publication number
- SG165157A1 SG165157A1 SG200607028-8A SG2006070288A SG165157A1 SG 165157 A1 SG165157 A1 SG 165157A1 SG 2006070288 A SG2006070288 A SG 2006070288A SG 165157 A1 SG165157 A1 SG 165157A1
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- genes
- identification
- virulence gene
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001018 virulence Effects 0.000 abstract 2
- 101100376046 Bacillus subtilis (strain 168) ydhE gene Proteins 0.000 abstract 1
- 101100183377 Escherichia coli (strain K12) mdtK gene Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108091008053 gene clusters Proteins 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 101150015622 pyk gene Proteins 0.000 abstract 1
- 101150053304 pykF gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9424921.6A GB9424921D0 (en) | 1994-12-09 | 1994-12-09 | Identification of genes |
GBGB9501881.8A GB9501881D0 (en) | 1995-01-31 | 1995-01-31 | Identification of genes |
GBGB9509239.1A GB9509239D0 (en) | 1995-05-05 | 1995-05-05 | Identification of genes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG165157A1 true SG165157A1 (en) | 2010-10-28 |
Family
ID=27267507
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG9801353A SG56084A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
SG200301515A SG119177A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
SG200607028-8A SG165157A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
SG2006070270A SG173213A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG9801353A SG56084A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
SG200301515A SG119177A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2006070270A SG173213A1 (en) | 1994-12-09 | 1995-12-11 | Identification of genes |
Country Status (21)
Country | Link |
---|---|
US (7) | US5876931A (ja) |
EP (3) | EP0796341B1 (ja) |
JP (3) | JP3522285B2 (ja) |
KR (4) | KR20060099543A (ja) |
CN (3) | CN1160469C (ja) |
AT (2) | ATE215986T1 (ja) |
AU (1) | AU711524C (ja) |
CA (2) | CA2623339C (ja) |
CZ (1) | CZ296981B6 (ja) |
DE (3) | DE889120T1 (ja) |
DK (2) | DK0889120T3 (ja) |
ES (2) | ES2178101T3 (ja) |
FI (1) | FI121601B (ja) |
HK (2) | HK1009833A1 (ja) |
HU (1) | HUT76975A (ja) |
NO (2) | NO320492B1 (ja) |
NZ (3) | NZ502020A (ja) |
PT (1) | PT889120E (ja) |
RU (1) | RU2370541C2 (ja) |
SG (4) | SG56084A1 (ja) |
WO (1) | WO1996017951A2 (ja) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996017951A2 (en) * | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
US6303115B1 (en) * | 1996-06-17 | 2001-10-16 | Microcide Pharmaceuticals, Inc. | Screening methods using microbial strain pools |
US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
NO974299D0 (no) * | 1997-09-18 | 1997-09-18 | Forskningsparken I Aas As | Metode for stabil merking av mikroorganismer |
EP0943681A1 (en) * | 1998-01-22 | 1999-09-22 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
AU2144499A (en) * | 1998-01-22 | 1999-08-09 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
WO1999045136A1 (en) * | 1998-03-05 | 1999-09-10 | University Of British Columbia | Methods for assaying type iii secretion inhibitors |
ATE333499T1 (de) * | 1998-03-18 | 2006-08-15 | Quark Biotech Inc | Selektion/subtraktionsansatz zur genidentifizierung |
AU4188199A (en) * | 1998-05-15 | 1999-12-06 | University Of California, Los Angeles | Type iii (bordetella) secretion system |
BR9914479A (pt) * | 1998-09-04 | 2001-06-26 | Creatogen Ag | Mutantes sp12 de salmonella atenuada como carreadores antìgenos |
US6309817B1 (en) | 1998-09-30 | 2001-10-30 | Boston Medical Center Corporation | Identification of virulence determinants activators in prokaryotic pathogens |
US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
US6299850B1 (en) | 1999-03-16 | 2001-10-09 | The United States Of America As Represented By The Department Of Energy | Carbon activation process for increased surface accessibility in electrochemical capacitors |
ES2439645T3 (es) | 1999-04-09 | 2014-01-24 | Zoetis P&U Llc | Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia |
US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
AU5559300A (en) * | 1999-07-06 | 2001-01-22 | Institut Pasteur | Method of making and identifying attenuated microorganisms, compositions utilizing the sequences responsible for attenuation, and preparations containing attenuated microorganisms |
US6589738B1 (en) | 1999-11-09 | 2003-07-08 | Elitra Pharmaceuticals, Inc. | Genes essential for microbial proliferation and antisense thereto |
US20030157121A1 (en) * | 2000-02-03 | 2003-08-21 | Chatfield Steven Neville | Virulence genes, proteins, and their use |
US6783985B1 (en) | 2000-02-18 | 2004-08-31 | Elitra Pharmaceuticals Inc. | Gene disruption methodologies for drug target discovery |
ES2244617T3 (es) | 2000-03-17 | 2005-12-16 | Pharmacia & Upjohn Co Llc | Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados. |
GB0008748D0 (en) * | 2000-04-11 | 2000-05-31 | Univ Manchester | Mutant bank |
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
US20020076722A1 (en) * | 2000-09-13 | 2002-06-20 | Neyfakh Alexander A. | Antibiotic hypersusceptibility mutations in bacteria |
US20020094536A1 (en) * | 2000-12-28 | 2002-07-18 | Cell Therapeutics, Inc. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
EP1390468A4 (en) * | 2001-04-23 | 2004-09-22 | Elitra Pharmaceuticals Inc | IDENTIFICATION OF ESSENTIAL GENES OF ASPERGILLUS FUMIGATUS AND METHOD OF USE |
ATE345386T1 (de) * | 2001-05-17 | 2006-12-15 | Creatogen Ag | Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben |
WO2002103513A1 (en) * | 2001-06-15 | 2002-12-27 | Chiron Corporation | Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents |
US7393539B2 (en) | 2001-06-22 | 2008-07-01 | Health Protection Agency | Mycobacterial antigens expressed under low oxygen tension |
CA2453173C (en) | 2001-07-04 | 2013-12-10 | Health Protection Agency | Mycobacterial antigens expressed during latency |
WO2003008631A2 (en) * | 2001-07-20 | 2003-01-30 | Health Protection Agency | Tagging of microorganisms |
US7026123B1 (en) | 2001-08-29 | 2006-04-11 | Pioneer Hi-Bred International, Inc. | UTR tag assay for gene function discovery |
GB0125535D0 (en) | 2001-10-24 | 2001-12-12 | Microbiological Res Authority | Mycobacterial genes down-regulated during latency |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
WO2003041734A1 (en) * | 2001-11-12 | 2003-05-22 | Pharmacia & Upjohn Company | Salmonella vaccine |
US20030170694A1 (en) * | 2001-12-21 | 2003-09-11 | Daniel Wall | Stabilized nucleic acids in gene and drug discovery and methods of use |
US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
PT1350796E (pt) * | 2002-04-05 | 2009-01-23 | Merial Sas | Bactérias gram-negativas atenuadas |
EP1499732A4 (en) * | 2002-04-15 | 2005-11-16 | Chiron Corp | ESSENTIAL AND IMPORTANT GENES OF PSEUDOMONAS AEROGINOSA, AND THEIR USE FOR THE DESIGN OR IDENTIFICATION OF ANTIBACTERIAL AGENTS |
AU2003278714A1 (en) * | 2002-08-20 | 2004-03-11 | Chiron Corporation | Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes |
FI116068B (fi) * | 2003-09-15 | 2005-09-15 | Fit Biotech Oyj Plc | Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi |
DE502004009871D1 (de) * | 2003-11-21 | 2009-09-17 | Merck Patent Gmbh | Verfahren zur modifikation von chiralen flüssigkri |
US20050266447A1 (en) * | 2004-04-19 | 2005-12-01 | Pioneer Hi-Bred International, Inc. | Method for identifying activators of gene transcription |
ATE537269T1 (de) | 2004-05-21 | 2011-12-15 | Univ California | Verfahren zur verbesserung der herstellung von isoprenoid-zusammensetzungen |
WO2007005604A2 (en) | 2005-07-05 | 2007-01-11 | The Regents Of The University Of California | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof |
EP1752532A1 (en) | 2005-08-09 | 2007-02-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Extracellular polyhydroxyalkanoates produced by genetically engineered microorganisms |
AU2007267033B2 (en) | 2006-05-26 | 2012-05-24 | Amyris, Inc. | Production of isoprenoids |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
US8257957B2 (en) | 2006-09-26 | 2012-09-04 | The Regents Of The University Of California | Production of isoprenoids and isoprenoid precursors |
WO2008153772A2 (en) * | 2007-05-25 | 2008-12-18 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
US8703153B2 (en) | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
US9051665B2 (en) * | 2008-11-20 | 2015-06-09 | Steven L. Zeichner | Method for screening biomolecules |
US10369772B2 (en) | 2012-07-10 | 2019-08-06 | Textron Innovations Inc. | Method of making core-stiffened structure |
US8715962B2 (en) | 2010-03-31 | 2014-05-06 | Codexis, Inc. | Production of geranyl diphosphate |
MX2012013037A (es) | 2010-05-10 | 2013-07-29 | Univ California | Composiciones de endorribonucleasa y metodos de uso de las mismas. |
US8829171B2 (en) | 2011-02-10 | 2014-09-09 | Illumina, Inc. | Linking sequence reads using paired code tags |
US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
WO2012106546A2 (en) | 2011-02-02 | 2012-08-09 | University Of Washington Through Its Center For Commercialization | Massively parallel continguity mapping |
US8481052B2 (en) * | 2011-05-17 | 2013-07-09 | Cj Cheiljedang Corporation | Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same |
JP6406581B2 (ja) | 2011-12-16 | 2018-10-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | オプシンポリペプチドおよびその使用法 |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
HUE048780T2 (hu) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Tauopátia kezelésére szolgáló módszerek |
WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
US8945562B2 (en) | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
EP3881868B1 (en) | 2013-02-15 | 2023-09-27 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
US10557133B2 (en) | 2013-03-13 | 2020-02-11 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
WO2014161988A1 (en) | 2013-04-05 | 2014-10-09 | Université Du Luxembourg | Biotechnological production of itaconic acid |
EA039554B1 (ru) | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
DK3083994T3 (da) | 2013-12-20 | 2021-09-13 | Illumina Inc | Bevarelse af genomisk konnektivitetsinformation i fragmenterede genomiske DNA-prøver |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
IL299976B1 (en) | 2014-10-17 | 2024-07-01 | Illumina Cambridge Ltd | Continuity-preserving transposition |
LT3280440T (lt) | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai |
WO2017037203A1 (en) | 2015-09-02 | 2017-03-09 | Immutep S.A.S. | Anti-LAG-3 Antibodies |
BR112018069075A2 (pt) | 2016-03-19 | 2019-01-29 | F1 Oncology Inc | métodos e composições para transduzir linfócitos e expansão regulada dos mesmos |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
IL262010B (en) | 2016-04-04 | 2022-09-01 | Bioverativ Usa Inc | Anti-complement factor bb antibodies and their uses |
CN109563507B (zh) | 2016-07-08 | 2024-03-05 | 埃克苏马生物技术公司 | 用于转导淋巴细胞及调节其活性的方法及组合物 |
EP3484348A4 (en) * | 2016-07-13 | 2021-11-24 | Psomagen, Inc. | MICROBIAL PHARMACOGENOMICS PROCESS AND SYSTEM |
PE20191031A1 (es) | 2016-10-12 | 2019-08-05 | Bioverativ Usa Inc | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
MX2019008503A (es) | 2017-01-18 | 2019-09-13 | F1 Oncology Inc | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. |
CA3054064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
CN110914416B (zh) | 2017-04-27 | 2023-07-21 | 加州大学董事会 | 产生大麻素和大麻素衍生物的微生物和方法 |
US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004202A1 (en) * | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
DD147855A5 (de) | 1978-12-22 | 1981-04-22 | Biogen Nv | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US5210035A (en) | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
US4550081A (en) * | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US5397697A (en) * | 1989-01-10 | 1995-03-14 | Ciba-Geigy Corporation | Identification of plant-responsive genes of bacteria |
FR2664614B1 (fr) * | 1990-07-11 | 1992-10-16 | Pasteur Institut | Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires. |
SE9101433D0 (sv) | 1991-05-13 | 1991-05-13 | Marianne Hansson | Recombinant dna sequence and its use |
AU2778992A (en) * | 1991-10-07 | 1993-05-03 | Idaho Research Foundation Inc., The | Genetic construct for selection of homologous recombinants on a single selective medium |
CA2123675A1 (en) | 1991-11-15 | 1993-05-27 | David W. Niesel | Membrane expression of heterologous genes |
US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
AU5591694A (en) | 1992-11-06 | 1994-06-08 | Regents Of The University Of Minnesota | Composition protective against (p. multocida) pasteurellosis infection |
WO1994026933A1 (en) * | 1993-05-13 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic footprinting: insertional mutagenesis and genetic selection |
US5700638A (en) | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
DE4405652A1 (de) * | 1994-02-22 | 1995-09-07 | Hoechst Ag | Verfahren zur Herstellung von nichtoxidischer Keramik mit definierter Wärmeleitfähigkeit |
AU3958895A (en) | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
US5700683A (en) * | 1995-02-17 | 1997-12-23 | Pathogenesis Corporation | Virulence-attenuating genetic deletions deleted from mycobacterium BCG |
EP0857214A1 (en) * | 1995-10-16 | 1998-08-12 | Smithkline Beecham Plc | Novel saliva binding protein |
CA2237581A1 (en) | 1995-11-14 | 1997-05-22 | The General Hospital Corporation | Salmonella secreted proteins and uses thereof |
AU4070097A (en) | 1996-08-16 | 1998-03-06 | Uab Research Foundation, The | Mucosal immunogens for novel vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
CA2280839A1 (en) | 1997-02-14 | 1998-08-20 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
GB9804809D0 (en) | 1998-03-06 | 1998-04-29 | Wallis Timothy S | Attenuated salmonella:materials and methods relating thereto |
US6585975B1 (en) | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
BR9914479A (pt) | 1998-09-04 | 2001-06-26 | Creatogen Ag | Mutantes sp12 de salmonella atenuada como carreadores antìgenos |
WO2000028038A2 (en) | 1998-11-09 | 2000-05-18 | Microscience Limited | Virulence genes and proteins, and their use |
GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
EP1226254A2 (en) | 1999-11-05 | 2002-07-31 | L'Unité de Recherche en Biologie Moléculaire (URBM) des Facultés Universitaires Notre Dame de la Paix (FUNDP) | Virulence genes, proteins, and their use |
NZ519669A (en) | 1999-12-23 | 2004-03-26 | Vmax Ltd | Streptococcus pyogenes virulence genes and proteins and their use |
GB0011108D0 (en) | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
US6548368B1 (en) * | 2000-08-23 | 2003-04-15 | Applied Materials, Inc. | Method of forming a MIS capacitor |
GB0127657D0 (en) | 2001-11-19 | 2002-01-09 | Microscience Ltd | Virulence genes and proteins and their use |
US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
-
1995
- 1995-12-11 WO PCT/GB1995/002875 patent/WO1996017951A2/en active IP Right Grant
- 1995-12-11 CN CNB951975757A patent/CN1160469C/zh not_active Expired - Fee Related
- 1995-12-11 SG SG9801353A patent/SG56084A1/en unknown
- 1995-12-11 CZ CZ0175597A patent/CZ296981B6/cs not_active IP Right Cessation
- 1995-12-11 JP JP51742896A patent/JP3522285B2/ja not_active Expired - Fee Related
- 1995-12-11 KR KR1020067017679A patent/KR20060099543A/ko not_active Application Discontinuation
- 1995-12-11 DK DK98201907T patent/DK0889120T3/da active
- 1995-12-11 ES ES98201907T patent/ES2178101T3/es not_active Expired - Lifetime
- 1995-12-11 AU AU41219/96A patent/AU711524C/en not_active Ceased
- 1995-12-11 US US08/637,759 patent/US5876931A/en not_active Expired - Lifetime
- 1995-12-11 KR KR1019970703866A patent/KR100445103B1/ko not_active IP Right Cessation
- 1995-12-11 EP EP95939362A patent/EP0796341B1/en not_active Expired - Lifetime
- 1995-12-11 KR KR1020037017326A patent/KR100551104B1/ko not_active IP Right Cessation
- 1995-12-11 DE DE0889120T patent/DE889120T1/de active Pending
- 1995-12-11 PT PT98201907T patent/PT889120E/pt unknown
- 1995-12-11 DE DE69526377T patent/DE69526377T2/de not_active Expired - Lifetime
- 1995-12-11 SG SG200301515A patent/SG119177A1/en unknown
- 1995-12-11 EP EP01205191A patent/EP1285960A3/en not_active Withdrawn
- 1995-12-11 DE DE69505011T patent/DE69505011T2/de not_active Expired - Lifetime
- 1995-12-11 CA CA2623339A patent/CA2623339C/en not_active Expired - Fee Related
- 1995-12-11 HU HU9701765A patent/HUT76975A/hu not_active Application Discontinuation
- 1995-12-11 RU RU2003135645/13A patent/RU2370541C2/ru not_active IP Right Cessation
- 1995-12-11 CN CN2006101006621A patent/CN1912141B/zh not_active Expired - Fee Related
- 1995-12-11 SG SG200607028-8A patent/SG165157A1/en unknown
- 1995-12-11 NZ NZ502020A patent/NZ502020A/xx not_active IP Right Cessation
- 1995-12-11 EP EP98201907A patent/EP0889120B1/en not_active Expired - Lifetime
- 1995-12-11 NZ NZ296581A patent/NZ296581A/en not_active IP Right Cessation
- 1995-12-11 AT AT98201907T patent/ATE215986T1/de active
- 1995-12-11 KR KR1020057005514A patent/KR20050052665A/ko not_active Application Discontinuation
- 1995-12-11 CN CNA031549489A patent/CN1510137A/zh active Pending
- 1995-12-11 SG SG2006070270A patent/SG173213A1/en unknown
- 1995-12-11 NZ NZ511170A patent/NZ511170A/en not_active IP Right Cessation
- 1995-12-11 DK DK95939362T patent/DK0796341T3/da active
- 1995-12-11 CA CA002206515A patent/CA2206515C/en not_active Expired - Fee Related
- 1995-12-11 ES ES95939362T patent/ES2126332T3/es not_active Expired - Lifetime
- 1995-12-11 AT AT95939362T patent/ATE171477T1/de active
-
1997
- 1997-05-30 NO NO19972468A patent/NO320492B1/no not_active IP Right Cessation
- 1997-06-06 FI FI972424A patent/FI121601B/fi not_active IP Right Cessation
- 1997-06-09 US US08/871,355 patent/US6015669A/en not_active Expired - Lifetime
-
1998
- 1998-09-15 HK HK98110640A patent/HK1009833A1/xx not_active IP Right Cessation
- 1998-12-01 US US09/201,945 patent/US6342215B1/en not_active Expired - Fee Related
-
2000
- 2000-11-16 US US09/714,602 patent/US6984490B1/en not_active Expired - Fee Related
-
2002
- 2002-08-02 JP JP2002226740A patent/JP4220195B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-01 NO NO20042249A patent/NO327361B1/no not_active IP Right Cessation
- 2004-08-09 HK HK07108847.1A patent/HK1100782A1/xx not_active IP Right Cessation
-
2005
- 2005-08-09 US US11/199,853 patent/US20060216309A1/en not_active Abandoned
-
2007
- 2007-08-17 US US11/840,903 patent/US7842290B2/en not_active Expired - Fee Related
-
2008
- 2008-05-21 JP JP2008133664A patent/JP2009005688A/ja active Pending
-
2010
- 2010-09-27 US US12/890,892 patent/US20110229515A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004202A1 (en) * | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
Non-Patent Citations (2)
Title |
---|
ETHANOLAMINE UTILIZATION IN SALMONELLA TYPHIMURIUM: NUCLEOTIDE SEQUENCE, PROTEIN EXPRESSION, AND MUTATIONAL ANALYSIS OF T * |
SIMULTANEOUS IDENTIFICATION OF BACTERIAL VIRULENCE GENES BY NEGATIVE SELECTION * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG165157A1 (en) | Identification of genes | |
EP1167542A3 (en) | Probe for diagnosing infectious disease arising from Enterococcus faecalis | |
IL106316A0 (en) | Process for categorising nucleotides sequence populations | |
YU61999A (sh) | Postupak za fermentacionu proizvodnju d-pantotenske kiseline uz primenu bakterija korijumskog oblika | |
EP0994190A3 (en) | DNA conferring L-homoserine resistance to bacteria, and its use | |
IL102765A (en) | Reagents and methods to detect and determine mycobacterium nucleic acids | |
GB9922124D0 (en) | Phosphodiesterase enzymes | |
HU9601448D0 (en) | Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof | |
NZ512835A (en) | Genes identified as required for proliferation in escherichia coli | |
AU2135497A (en) | Genetic markers and methods for the detection of escherichia coli serotype-0157:h7 | |
EP0769553A4 (en) | DNA FRAGMENT, RECOMBINANT VECTOR THAT CONTAINS IT AND METHOD FOR EXPRESSING FOREIGN GENES WITH ITS USE | |
AU6724794A (en) | GRB3-3 gene, its variants and their uses | |
ZA99236B (en) | Orotidine-5'-phosphate decarboxylase gene, gene construct comprising this gene and its use. | |
ATE488601T1 (de) | Nukleotidsequenzen zum nachweis von enterohämorrhagischer escherichia coli | |
Miflin et al. | Molecular characterization of isolates of Haemophilus paragallinarum from China by ribotyping | |
AU782261C (en) | Novel glycosyltransferase genes | |
EP1010757A3 (en) | Insertion sequence from Methylococcus capsulatus | |
DE60032328D1 (de) | Verfahren zur herstellung von coenzym q 10 | |
AU2002214949A1 (en) | Nucleotide sequences which code for the ppsa gene | |
GB9724627D0 (en) | Gram positive microorganism formate pathway | |
GB9828711D0 (en) | Production of proteins in gram-positive microorganisms | |
EP1336657A4 (en) | PROCESS FOR PREPARING COENZYME Q 10 | |
WO1993018151A1 (fr) | Element transposable originaire d'une bacterie du genre brevibacterium | |
AU9350298A (en) | Novel gene defective in apeced and its use | |
MXPA01001639A (es) | Antigenos de chlamydia y los correspondientes fragmentos de adn y usos de los mismos. |